Second Sight Medical Products

Vivani Medical, Inc. develops and commercializes drug and device implants that treat patients with chronic diseases with high unmet medical need. The company was founded on May 22,2003 and is headquartered in Emeryville, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. It operates under the Biopharm Division and Neuromodulation Division segments. The company was founded by Adam Mendelsohn on May 22, 2003 and is headquartered in Alameda, CA.

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by over 30% during intraday trading. This is why it happened.

EYES Stock: Over 30% Increase Intraday Explanation

Lucira Health

Ra Medical Systems Inc

Second Sight Medical Products, Inc. (NASDAQ: EYES), Lucira Health, Inc. (NASDAQ: LHDX) and Ra Medical Systems, Inc. (NYSE: RMED) were among the biggest health care gainers Wednesday. Second Sight Rallies On Positive Results For Visual Prosthesis: Second Sight, which makes implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced two-year results for the early feasibility study of its Orion Visual Cortical Prosthesis.

Why Second Sight Medical, Lucira Health, RA Medical Are Moving Today

Second Sight Medical Products Inc. (NASDAQ: EYES) shares gapped up Wednesday morning following the two-year results from the company's Orion Study in visual prosthetics.  Four out of five patients are able to better identify the direction of motion of a bar moving across a computer screen with the Orion System on, with only one adverse event occurring.

What To Watch For As Second Sight Stock Gaps Higher On Vision Study Results

Cellect Biotechnology Ltd

Borr Drilling Ltd

These penny stocks moved in early morning trading; will you add them to your watchlist? The post Are These Penny Stocks The Biggest Morning Movers?

Are These Penny Stocks The Biggest Morning Movers?

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced two-year results of its Early Feasibility Study (Study) of the Orion Visual Cortical Prosthesis (Orion). The Study is a single arm six subject study at UCLA and Baylor College of Medicine. The Study was paused due

Second Sight Medical Products Announces Two-Year Results of its Orion Study

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) fell by over 6% pre-market. This is why it happened.

EYES Stock: Over 6% Decrease Pre-Market Explanation

Blink Charging

Arcimoto

Ontrak

Root

Short-covering has become one of the hottest buzzwords of the year. Here are 5 stocks with some of the highest shorts on the market.

5 Heavily Shorted Stocks to Watch Carefully

AMC Entertainment

ChargePoint Holdings

Investors are clamoring to find the next GameStop. Of the most shorted stocks right now, these are the candidates most primed for a squeeze.

Most Shorted Stocks: Could EYES, BLNK, DISCA or CLVS Be the Next GameStop?

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by 27.43%. This is why it happened.

Second Sight Medical Products Stock Price Increased 27.43%: Why It Happened

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the “Company” or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company's Board of Directors has appointed two new members, Dr. Dean Baker and Ms. Alexandra Larson. Dr. Baker has also been appointed to the Audit Committee of the Board. “We are honored and excited to a

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

Termination of the business combination with Second Sight Medical Products, Inc.

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company's Board of Directors has named Scott Dunbar to replace Matthew Pfeffer as acting Chief Executive Officer (“CEO”). Under Nasdaq rules, an independent director may temporarily be named acting CEO, b

Second Sight Medical Products Names Scott Dunbar Acting CEO

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or “Second Sight”), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has closed its previously announced private placement, which resulted in gross proceeds to Second Sight of $27.9 million, before deducting offering expenses. The net proceeds from the private placement are

Second Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock

Second Sight Will Probably Take a Second Look at Giving Up Control. EYES stock will probably rise if the company backs off of the sale of 60% to Pixium Vision.

Second Sight May Take Another Look at Giving Up Control

Add in the pending capital raise, and dilution concerns are on the table as well. Speculative mania over low-priced stocks may help it hold onto most of its gains.

Let Second Sight Stock Give Back a Little More Before Jumping In

LiveXLive Media

Livexlive Media Inc (NASDAQ: LIVX) shares are trading higher after the company announced it's launching a series of pay-per-view shows on Facebook's new paid online event feature spanning comedy, sports and podcasting to be marketed globally. LiveXLive Media is devoted to live music and music-related video content.

What's Happening With LIVX Stock And EYES Stock Wednesday?

Shares of Second Sight Medical Products Inc. tumbled 25% to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private placement of common stock. The share sale comes after the stock skyrocketed more than 6-fold month to date through Tuesday, after the company's Argus 2s Retinal Prosthesis System was approved by the Food and Drug Administration.

Second Sight Medical stock tumbles after private placement of stock at 46% discount

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) fell by over 20% pre-market. This is why it happened.

EYES Stock Price Falls Over 20% Pre-Market: Why It Happened

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it has entered into definitive securities purchase agreements with accredited investors for a private placement that will result in gross proceeds to Second Sight of $27.9 million, before deducting placement

Second Sight Medical Products Announces $27.9 Million Private Placement of Common Stock

EYES stock jumped higher off a very encouraging FDA approval but now is the time to apply a little more scrutiny to the Second Sight Medical investment. The post Second Sight Medical Products Is No Short Squeeze appeared first on InvestorPlace.

Second Sight Medical Products Is No Short Squeeze

You won't believe your eyes when you see the ultra-bullish price action in EYES stock, along with the game-changing regulatory announcement. The post FDA Approval Sheds New Light on Second Sight Medical Products appeared first on InvestorPlace.

FDA Approval Sheds New Light on Second Sight Medical Products

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by 486.07% over the past month. This is why it happened.

EYES Stock Price Increased 486.07% Over The Past Month: Why It Happened

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by 35.71% yesterday. This is why it happened.

EYES Stock Price Increases 35.71%: Why It Happened

Shares of Second Sight Medical Products Inc. shot up 30.7% to $15.38 on volume of 56.6 million shares in morning trading Tuesday, bringing its three-day gain to 975.5%, in the wake of the company's announcement that the Food and Drug Administration approved its Argus 2s Retinal Prosthesis System for the treatment of retinitis pigmentosa. The stock skyrocketed a record 304.9% on record volume of 739.7 million shares on March 5 after the announcement, then 103.3% on volume of 320.4 million shares on Monday, before Tuesday's gain.

Second Sight Medical stock soars nearly 1,000% in 3 days

The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) is trading at over 30% pre-market. This is why it happened.

News for Second Sight Medical Products Stock (EYES)